SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

The Vietnam Vaccine Joint Stock Company (VNVC) and Sanofi on October 8 signed a document guiding the cooperation in ...

Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant ...

Wyoming’s attorney general, through a settlement with a French multinational pharmaceutical and health care company, has ...

The American private equity firm has agreed to French government demands about protecting jobs and investment in France.View ...

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of ...

Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.